Skip navigation

Build your next trial with the leader in MRD

Natera's precision diagnostics portfolio detects the signals that power the decisions to change cancer's trajectory

Advance your Drug Development

Trusted by top drug developers,
researchers, and clinicians worldwide

  • Unmatched commercial scale

    #1 MRD Test

    commercially ordered1

  • Scientific Leadership

    90%

    of MRD peer-reviewed publications use Natera assays2

  • Proven Regulatory Expertise

    First and Only

    FDA-approved, IVDR-certified, and PMDA-approved MRD assay†‡*

Multiple pharma-partnered MRD-guided interventional trials with CDx intent1

View studies

Powering all stages of drug development

  • Discovery


    Biomarker discovery

    Discover and validate biomarkers with RWD linked to deep genomic context.

  • Development


    Trial design & feasibility

    Inform study design & feasibility, optimize site selection, and match eligible patients to trials.

  • Development


    Market-leading precision diagnostics

    Measure treatment response and evaluate resistance mechanisms with ultrasensitive MRD and CGP.

  • Commercialization


    Eligible patient identification

    Identify eligible patients for approved therapies via real-time alerts.

Oncology Biopharma Solutions

The most comprehensive ecosystem of precision diagnostics and real-world data

Molecular Residual Disease Assays

  • Signatera™ Genome

    Tumor-informed Ultrasensitive MRD

    The only ultrasensitive MRD assay that tracks Phased, Structural, and Single Nucleotide Variants, with detection below 0.1 PPM3

    Explore more

  • Clarity™ Heme

    Tumor-informed Ultrasensitive MRD

    Plasma-informed fixed panel powered by personalized PV tracking for limit of detection (LOD95) below 1 PPM.5

    Explore more

  • Latitude™ PanTumor

    Tissue-free MRD

    Rapid and sensitive methylation-based ctDNA assay for metastatic settings and as a reflex from Signatera when tissue is unavailable.4

    Explore more

Comprehensive Genomic Profiling (CGP)

Stand-alone or add either to any MRD test

  • Altera™ Tissue

    Tissue-based whole exome and whole transcriptome sequencing

    Explore more

  • Altera™ Liquid

    Plasma-based targeted panel of 523 genes. Reflex liquid CGP to complement tumor-informed ctDNA monitoring.6

    Explore more

Data & Trial Solutions

  • MIIRA™ Real-World Data (RWD)

    Largest multi-modal RWD platform in early-stage cancer, linking Signatera MRD timepoints with clinico-genomic context for translational discovery and curative-intent drug development7

    Explore more

  • Trial Design & Patient Identification

    Convert the largest clinical testing footprint into real-time trial enrollment with feasibility testing, site selection, and real-time patient matching

    Explore more

Join us in building the future

From enrichment to response monitoring, Natera is experienced with MRD-powered trial design
at every phase of development.

  • Cancer type
    GU cancers
    Furthest phase
    Approval
    Milestone
    1st FDA-approved MRD CDx
  • Cancer type
    Pan-tumor
    Furthest phase
    Approval
    Milestone
    1st PMDA-approved MRD test in Japan
  • Cancer type
    GI cancers
    Furthest phase
    Phase III
  • Cancer type
    GI cancers
    Furthest phase
    Phase III
  • Cancer type
    GI cancers
    Furthest phase
    Phase III
  • Cancer type
    GI cancers
    Furthest phase
    Phase III
  • Cancer type
    GI cancers
    Furthest phase
    Phase III
  • Cancer type
    Breast cancer
    Furthest phase
    Phase III
  • Cancer type
    Pan-tumor
    Furthest phase
    Phase III
  • Cancer type
    Pan-tumor
    Furthest phase
    Phase II to III
  • Cancer type
    GI cancers
    Furthest phase
    Phase II
  • Cancer type
    GI cancers
    Furthest phase
    Phase II
  • Cancer type
    GI cancers
    Furthest phase
    Phase II
  • Cancer type
    GI cancers
    Furthest phase
    Phase II
  • Cancer type
    Breast cancer
    Furthest phase
    Phase II
  • Cancer type
    Breast cancer
    Furthest phase
    Phase II
  • Cancer type
    Breast cancer
    Furthest phase
    Phase II
  • Cancer type
    Breast cancer
    Furthest phase
    Phase II
  • Cancer type
    Breast cancer
    Furthest phase
    Phase II
  • Cancer type
    Ovarian cancer
    Furthest phase
    Phase II
  • Cancer type
    Pan-tumor
    Furthest phase
    Phase I
    Milestone
    Obs.
Explore Signatera data

Latest Updates

  • Natera at ESMO

    Access Natera's latest product updates and data presented at ESMO

    View Presentations

  • Launch of AFT-NAVIGATE breast cancer trial

    Global, randomized, Phase III Trial evaluating Genentech's oral SERD with Signatera-guided CDK4/6 inhibitor therapy

    Read

  • First MRD companion diagnostic approved in Japan

    Japan's PMDA has approved Signatera as a CDx to guide adjuvant atezolizumab in MIBC.

    Read

  • Natera and Angiex partner on ADC response assessment

    Signatera™ will be used to assess response to an investigational nuclear-delivered antibody drug conjugate.

    Learn more

  • Signatera™ earns first-of-its-kind EU regulatory milestone

    Signatera's IVDR certification reduces the regulatory groundwork for partners launching clinical trials in Europe.*

    Learn more

  • Signatera™ is the 1st and Only MRD Test Approved in Japan

    Japan's PMDA has granted regulatory approval for Signatera™ in CRC.‡

    Learn more

We believe innovative and accurate diagnostics lead to life-changing cancer care.

Guided by science and a shared commitment to patients, we serve as a trusted partner to biopharma across every stage of drug development.

* Indicates a required field

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

  1. Based on RBC Capital Markets analyst estimates (June 2026) and data on file (September 2026)
  2. Of peer-reviewed publications for commercially available MRD assays, as of May 2026
  3. Analytical limit of detection demonstrated by Signatera Genome in a cell line dilution study. Signatera Genome with PVs and SVs available as a Research Use Only (RUO) assay, Natera internal data.
  4. Latitude™ PanTumor available for RUO and Investigational Use Only (IUO) only. Natera data on file.
  5. Clarity™ available as Research Use Only (RUO) and Clinical Laboratory Improvement Amendments (CLIA)-validated assays.
  6. Altera™ Liquid available for Research Use Only (RUO) and Investigational Use Only (IUO).
  7. Based on publicly available information. Based on de-identified patient information, data on file as of October 7 2026.
  • Signatera™ CDx is an FDA approved Companion Diagnostic test intended to identify Muscle Invasive Bladder Cancer (MIBC) patients with ctDNA MRD positive status who may benefit from atezolizumab. For the approved intended use, product limitations and detailed performance characteristics, refer to FDA approved labeling under the PMA #P260004.
  • PMDA Approval Number: 30800BZI00018000.
  • First EU IVDR for solid-tumor, tumor-informed ctDNA MRD.

Other tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. These tests have not been cleared or approved by the FDA. The laboratories are regulated under CLIA as qualified to perform high-complexity testing. CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test.
The tests have not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified.
© 2026 Natera, Inc. All Rights Reserved.

Privacy Policy Do Not Share My Personal Information California Notice at Collection HIPAA Notice IT Security Compliance Terms Licenses
icon-angle icon-bars icon-times